At a glance
- Originator Roche; University of Vermont
- Class Antineoplastics
- Mechanism of Action DNA inhibitors; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 07 Mar 2007 Discontinued - Preclinical for Cancer in Italy (unspecified route)
- 07 Mar 2007 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 14 Feb 2001 No-Development-Reported for Cancer in Italy (Unknown route)